Delcath Systems, Inc. to Host Analyst Meeeting

NEW YORK, May 30, 2012 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that the Company will host an Analyst Symposium on Chemosaturation Therapy on Friday, June 1, 2012 from 10:30 am to 1:30 pm ET (9:30 am to 12:30 p.m. CT). An internationally recognized panel of experts on innovative treatments for patients with cancers of the liver will discuss the impact of Delcath’s chemosaturation therapy on the treatment paradigm for cancers in the liver. The event will be held in Chicago, IL immediately prior to the American Society of Clinical Oncology (ASCO) annual meeting. Attendance is by invitation only.

A live webcast of the event will be available from the Investor Relations section of the Company’s website at www.delcath.com. A replay will be available for ninety days after the event.

Featured speakers include:

• Eamonn Hobbs, President & CEO, Delcath Systems Inc.
• Richard Alexander, MD - Surgical Oncologist, Associate Chairman for Clinical Research, Surgery, University of Maryland Medical Center
• Fred Moeslein, MD, PH.D Interventional Radiologist, Interim Director, Interventional Neuroradiology, University of Maryland Medical Center
• Alessandro Testori, MD - Surgical Oncologist at IEO; Director, Division of Melanoma and Skin-Muscle Sarcoma, European Institute of Oncology, Milan, Italy
• Pier Francesco Ferrucci, MD Medical Oncologist at IEO; Director, Translational Research on Melanoma unit, European Institute of Oncology, Milan, Italy
• Stephen O’Day, MD - Director, the Los Angeles Skin Cancer Institute; Director, Clinical Research, The Beverly Hills Cancer Center; Clinical Associate Professor of Medicine, USC Keck School of Medicine

About Delcath Systems

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Delcath’s proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company’s initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath announced that its randomized Phase III clinical trial for patients with metastatic melanoma in the liver had successfully achieved the study’s primary endpoint of extended hepatic progression-free survival. The Company also completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Delcath Hepatic CHEMOSAT® delivery system in April 2011 and for the second generation hemofiltration cartridge for CHEMOSAT in April 2012. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT system in Europe. The Company has not yet received FDA approval for commercial sale of its system in the United States. The Company continues with the preparation of its NDA submission and intends to seek FDA approval for commercial sale of its chemosaturation system with melphalan. For more information, please visit the Company’s website at www.delcath.com.

Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the benefits of the Generation 2 CHEMOSAT system and market acceptance of the same, patient outcomes using the Generation 2 system, the timing of the supply and distribution of the CHEMOSAT system to early launch centers in Europe, the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company’s NDA by the FDA, approval of the Company’s NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, acceptance of our IND amendment, the timing and use, if any, of the line of credit from SVB, and our ability to access this facility, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

SOURCE Delcath Systems, Inc.